US Edition
GSK sees latest Nucala approval as the first shot in a long-term war to deconstruct and personalize COPD treatment - Drug Discovery and Development
Summary by Drug Discovery and Development
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
GSK sees latest Nucala approval as the first shot in a long-term war to deconstruct and personalize COPD treatment - Drug Discovery and Development
Chronic obstructive pulmonary disease, a condition CDC estimates affects about 14.2 million (6.5%) U.S. adults, can be brutal. And for patients with COPD, exacerbations are an acute risk, a sudden flare-up where breathing becomes a potentially life-threatening struggle against inflamed airways. “Anecdotally… if I reflect back on some of my experiences in… emergency medicine departments… The post GSK sees latest Nucala approval as the first shot …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
